MOntelukast as a Potential CHondroprotective Treatment Following Anterior Cruciate Ligament Reconstruction (MOCHA Trial)
Eligible age
25–50 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a multicenter randomized, placebo-controlled trial to assess whether a 6-month course of oral montelukast after ACL reconstruction reduces systemic markers of inflammation and biochemical and imaging biomarkers of cartilage degradation. This study will specifically target older ACL reconstruction patients with concomitant meniscal injuries as this group is at greatest risk of rapid PTOA progression. Patients will randomly be assigned to receive oral montelukast (10 mg) versus placebo daily for 6 months after surgery.
Sponsor: Austin V Stone
You may qualify if…
- ✓ 1. Undergoing primary ACL reconstruction
- ✓ 2. Age between 25-50
- ✓ 3. Concomitant meniscus injury
You may not qualify if…
- ✕ 1. Undergoing revision procedures
- ✕ 2. Multiple ligament injuries requiring multiple ligament reconstruction/repair
- ✕ 3. Depressive symptoms and/or those who endorse suicidal ideation at the time of enrollment (PHQ-9 score \>= 15)
- ✕ 4. Found to not have a meniscus tear at the time of surgery
Where it's recruiting
Lexington
Source: ClinicalTrials.gov · NCT04572256 · last updated 2026-06-10